Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy

被引:14
|
作者
Bedke, Jens [1 ]
Chun, Felix K-H [3 ]
Merseburger, Axel [4 ]
Scharpf, Marcus [2 ]
Kasprzyk, Kathrin [1 ]
Schilling, David [1 ]
Sievert, Karl-Dietrich [1 ]
Stenzl, Arnulf [1 ]
Kruck, Stephan [1 ]
机构
[1] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[4] Hannover Med Sch, Dept Urol & Urooncol, Hannover, Germany
关键词
renal cell cancer; systemic inflammation; biomarkers; CRP; WBC; threshold; predictive accuracy; CANCER-SPECIFIC SURVIVAL; VALIDATION; BIOMARKER; MORTALITY; IMPACT; MODEL;
D O I
10.1111/j.1464-410X.2012.11642.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To re-evaluate the prognostic and predictive significance of the preoperative white blood cell (WBC) count and C-reactive protein (CRP) that independently predicts patient prognosis and to determine optimal threshold values for CRP. PATIENTS AND METHODS From 1996 to 2005, 327 patients with surgery for clear cell renal cell carcinoma were retrospectively evaluated. Cox proportional hazard models were used, adjusted for the effects of tumour stage, size, Fuhrman grade and Karnofsky index, to evaluate the prognostic significance of WBC count and CRP and to identify threshold values. Identified thresholds were correlated with clinicopathological parameters and used to estimate cancer-specific survival. To prove any additional predictive accuracy of the identified threshold it was compared with a clinicopathological base model using the Harrell concordance index (c-index). RESULTS In univariable analyses WBC count was a significant prognostic marker at a concentration of 9.5/mu L (hazard ratio [HR] 1.83) and 11.0/mu L (HR 2.09) and supported CRP values of 0.25 mg/dL (HR 6.47, P < 0.001) and 0.5 mg/dL (HR 7.15, P < 0.001) as potential threshold values. If adjusted by the multivariable models WBC count showed no clear breakpoint, but a CRP value of 0.25 mg/dL (HR 2.80, P = 0.027) proved to be optimal. Reduced cancer-specific survival was proved for CRP 0.25 mg/dL (median 69.9 vs 92.3 months). Median follow-up was 57.5 months with 72 (22%) tumour-related deaths. The final model built by the addition of CRP 0.25 mg/dL did not improve predictive accuracy (c-index 0.877) compared with the clinicopathological base model (c-index 0.881) which included TNM stage, grading and Karnofsky index. CONCLUSIONS Multivariable analyses revealed that an optimal breakpoint of CRP at a value of 0.25 mg/dL was best to stratify patients at risk of cancer-specific mortality, but CRP 0.25 mg/dL added no additional information in the prediction model. Therefore we cannot recommend measuring CRP as the traditional parameters of TNM stage, grading and Karnofsky index are already of high predictive accuracy.
引用
收藏
页码:E771 / E777
页数:7
相关论文
共 50 条
  • [31] Prognostic impact of C-reactive protein kinetics for advanced renal cell carcinoma treated with sunitinib
    Fujita, Tetsuo
    Tabata, Ken-ichi
    Ishii, Daisuke
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A novel preoperative inflammatory marker prognostic score in patients with clear cell and non-clear cell renal cell carcinoma.
    Sekar, Rishi Robert
    Patil, Dattatraya
    Pearl, Jeff
    Baum, Yoram
    Kucuk, Omer
    Harris, Wayne B.
    Carthon, Bradley
    Alemozaffar, Mehrdad
    Filson, Christopher Paul
    Ogan, Kenneth
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [33] Re: Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
    Canda, Abdullah Erdem
    JOURNAL OF UROLOGY, 2010, 184 (04): : 1570 - 1570
  • [34] Racial disparity in preoperative C-reactive protein level for predicting prognosis of patients with non-metastatic clear cell renal cell carcinoma: INMARC study
    Chen, Wei
    Tanaka, Hajime
    Kobayashi, Masaki
    Fukuda, Shohei
    Nakayama, Akinori
    Meagher, Margaret F.
    Yoshida, Soichiro
    Derweesh, Ithaar H.
    Master, Viraj A.
    Hirakawa, Akihiro
    Fujii, Yasuhisa
    Saito, Kazutaka
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [35] Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma COMMENT
    Campbell, Steven C.
    Lane, Brian R.
    JOURNAL OF UROLOGY, 2010, 183 (02): : 485 - 485
  • [36] Malondialdehyde and C-reactive protein as prognostic markers of hepatocellular carcinoma
    Elbaz, S.
    Mousa, N.
    Besheer, T.
    Sheta, T.
    Taha, K.
    Awad, M.
    Effat, N.
    Elgamal, A.
    Abdel-Razik, A.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2020, 77 (02) : 94 - 96
  • [37] Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma
    Gao, Jie
    Agizamhan, Sezim
    Zhao, Xiaozhi
    Jiang, Bo
    Qin, Haixiang
    Chen, Mengxia
    Guo, Hongqian
    FUTURE ONCOLOGY, 2019, 15 (13) : 1459 - 1468
  • [38] INVESTIGATION OF PREOPERATIVE SERUM C-REACTIVE PROTEIN LEVEL ON THE PROGNOSIS FOR PATIENTS WITH LOCALIZED RENAL CELL CARCINOMA
    Mugiya, Soichi
    Ozono, Seiichiro
    Nagata, Masao
    Takayama, Tatsuya
    Kurita, Yutaka
    JOURNAL OF UROLOGY, 2009, 181 (04): : 353 - 354
  • [39] Investigation of preoperative serum C-reactive protein elevation in recurrence for patients with localized renal cell carcinoma
    Mugiya, Soichi
    Ozono, Seiichiro
    Nagata, Masao
    Takayama, Tatsuya
    Ushiyama, Tomomi
    JOURNAL OF UROLOGY, 2008, 179 (04): : 375 - 375
  • [40] Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma
    Khattak, Muhammad A.
    Bakr, Farrah
    Krzystanek, Marcin
    Szallasi, Zoltan
    Gerlinger, Marco
    Santos, Claudio
    Swanton, Charles
    Pickering, Lisa M.
    Gore, Martin E.
    Larkin, James M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 971 - 972